Equipoise 400 by Meditech Human Pharmaceuticals is an ultra-high-concentration injectable anabolic steroid containing Boldenone Undecylenate at a heavy density of 400mg/ml in a 10ml multi-dose vial (4,000mg total active compound). Boldenone Undecylenate (globally recognized under its classic trade name Equipoise or EQ) is a structural derivative of testosterone engineered to deliver steady, high-quality, lean muscle accretion with reduced estrogenic activity and minimal water retention.
Formulated at nearly double the standard market concentration ($250\text{mg/ml}$), Meditech’s 400mg/ml variant is engineered for maximum volume efficiency—allowing advanced users to administer high weekly amounts of Boldenone in significantly smaller liquid injection volumes. Featuring the long-acting Undecylenate ester, it provides extended release kinetics that support steady muscle growth, dramatic vascularity, enhanced appetite, and high red blood cell elevation.
Key Benefits & Applications
-
Ultra-High Concentration Volume Efficiency: Packing 400 mg into every 1 mL allows high-dose weekly protocols (e.g., 600 mg to 800 mg) to be achieved in tiny liquid volumes (1.5 mL to 2 mL total per week), significantly reducing injection fluid volume and tissue stress.
-
Consistent Lean Tissue Accumulation: Promotes steady, dry muscle growth without severe fluid retention or bloating, yielding a dense, firm, and highly defined muscular appearance.
-
Massive Erythropoietin (EPO) & Stamina Elevation: Strongly stimulates renal red blood cell production, maximizing intramuscular oxygen delivery, delaying fatigue during heavy training, and producing pronounced vascularity.
-
Appetite Stimulation: Widely recognized for noticeably increasing appetite, assisting athletes and bodybuilders who struggle to consume sufficient caloric intake during high-volume growth phases.
-
Multi-Dose Vial Versatility: Rubber-stoppered 10ml vial allows for precise volume micro-adjustments using standard syringes across long cycles.






Reviews
There are no reviews yet.